Xponance, Inc. Alkermes Plc. Transaction History

Xponance, Inc.

$10.2 Billion
Q3 2024

A detailed history of Xponance, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Xponance, Inc. holds 17,578 shares of ALKS stock, worth $505,894. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,578

Previous 16,694 5.3%

Holding current value

$505,894

Previous $402,000 22.39%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$23.01 - $28.55 $20,340 - $25,238	884 Added 5.3%	17,578 $492,000
Q2 2024 Aug 14, 2024	SELL	$23.21 - $27.24 $6,057 - $7,109	-261 Reduced 1.54%	16,694 $402,000
Q1 2024 May 13, 2024	BUY	$26.4 - $32.56 $1,848 - $2,279	70 Added 0.41%	16,955 $458,000
Q4 2023 Jan 31, 2024	SELL	$23.37 - $28.68 $3,318 - $4,072	-142 Reduced 0.83%	16,885 $468,000
Q3 2023 Oct 23, 2023	BUY	$27.17 - $31.97 $8,748 - $10,294	322 Added 1.93%	17,027 $476,000
Q2 2023 Jul 13, 2023	BUY	$28.34 - $33.63 $182,878 - $217,014	6,453 Added 62.94%	16,705 $522,000
Q1 2023 Apr 17, 2023	BUY	$25.31 - $29.02 $2,227 - $2,553	88 Added 0.87%	10,252 $289,000
Q4 2022 Jan 23, 2023	BUY	$21.94 - $26.24 $9,368 - $11,204	427 Added 4.39%	10,164 $0
Q3 2022 Oct 24, 2022	BUY	$22.0 - $31.87 $15,642 - $22,659	711 Added 7.88%	9,737 $217,000
Q2 2022 Aug 02, 2022	BUY	$26.4 - $30.54 $31,627 - $36,586	1,198 Added 15.3%	9,026 $269,000
Q1 2022 Apr 20, 2022	BUY	$23.07 - $27.99 $180,591 - $219,105	7,828 New	7,828 $206,000
Q4 2021 Jan 31, 2022	SELL	$21.47 - $32.08 $176,418 - $263,601	-8,217 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$23.37 - $32.13 $18,415 - $25,318	-788 Reduced 8.75%	8,217 $253,000
Q2 2021 Aug 12, 2021	BUY	$18.78 - $25.15 $169,113 - $226,475	9,005 New	9,005 $221,000

Others Institutions Holding ALKS

# of Institutions

361

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Xponance, Inc. with notifications on news.

Account